Flowvium
返回探索器

Novo Nordisk

NVOleader

Novo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.

分享:
⇄ Compare

產品與營收

產品營收佔比

營收結構 ($42.6B)

靜態數據（加載即時財務…）

GLP-1 Diabetes (Ozempic, Rybelsus) (42%)
Obesity (Wegovy) (25%)
Insulin (20%)
Rare Disease & Other (13%)

業務部門構成與主要客戶

產品詳情

Ozempic (semaglutide injection)32%

GLP-1 receptor agonist for type 2 diabetes

Wegovy (semaglutide for obesity)25%

GLP-1 agonist approved for chronic weight management

Rybelsus (oral semaglutide)8%

First oral GLP-1 for type 2 diabetes

Insulin Portfolio (Tresiba, NovoRapid)20%

Long-acting and rapid-acting insulin products

Rare Blood Disorders8%

Hemophilia treatments (NovoSeven, Esperoct)

供應鏈關係

競爭對手

Eli Lilly and Company

GLP-1 / obesity drugs

影響: Primary competitor — GLP-1 duopoly

Pfizer Inc.

Obesity and metabolic drugs

影響: Pfizer developing oral GLP-1

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

供應鏈問題

↑ 생산 확대Wegovy 생산 캐파 2배 증설 완료
2026-04

덴마크·미국·프랑스 3개 공장 증설 완료로 Wegovy 공급 부족 해소. 2026Q2부터 대기 처방 소화 본격화.

★ 기회Amycretin(GLP-1+GIP) 3상 진입 — 차세대 파이프라인
2026-03

주1회 경구 복합제 Amycretin 3상 진입. 체중감소 효과 Wegovy 대비 +5%p 기대, 2028년 허가 목표.

機構訊號

機構操作價值季度申報日期
BlackRockreducing$163K2024.062024-08-13↓
BlackRockaccumulating$200M2024.062024-08-13↑
BlackRockreducing$23M2024.062024-08-13↓
BlackRockreducing$649K2024.062024-08-13↓
BlackRockreducing$8M2024.062024-08-13↓
BlackRockaccumulating$59M2024.062024-08-13↑
BlackRockreducing$2M2024.062024-08-13↓
BlackRockaccumulating$487M2024.062024-08-13↑
BlackRockreducing$2M2024.062024-08-13↓
BlackRockreducing$314K2024.062024-08-13↓
BlackRockreducing$7M2024.062024-08-13↓
BlackRockreducing$41M2024.062024-08-13↓
BlackRockreducing$3M2024.062024-08-13↓
BlackRockreducing$3M2024.062024-08-13↓
BlackRockreducing$228K2024.062024-08-13↓
BlackRockreducing$24M2024.062024-08-13↓
State Streetaccumulating$306M2025.122026-02-13↑
FMR (Fidelity)accumulating$182M2025.122026-02-17↑
FMR (Fidelity)reducing$23K2025.122026-02-17↓
FMR (Fidelity)accumulating$254M2025.122026-02-17↑
FMR (Fidelity)reducing$16M2025.122026-02-17↓
FMR (Fidelity)accumulating$58M2025.122026-02-17↑

機構持股狀況

13F基準 · Q4 2025
機構變動持股比例上季度持股數市值SEC
Capital Group維持1.80%—92.0M股$4,200M13F
Wellington增持0.69%—35.0M股$1,600M13F
Baillie Gifford維持0.52%—26.0M股$1,200M13F
Fidelity Contrafund增持0.47%—24.0M股$1,100M13F
追蹤機構合計持股比例: 3.48%合計市值: $8,100MSEC EDGAR 13F-HR基準 · 45天延遲披露

最新新聞

載入新聞中...

AI 分析

點擊「取得 AI 分析」以獲得 Novo Nordisk 的 AI 供應鏈分析。

企業資訊

總部

Bagsvaerd, Denmark

成立時間

1923

員工人數

64,000+

新聞盲區評分

盲區評分38
低盲區高盲區

機構活動

84

媒體評分

62

連鎖位置

連鎖中的角色

first follower

典型延遲

0-1 trading days

Novo Nordisk and Lilly form a GLP-1 duopoly; positive class data lifts both, while competitive data creates relative winners and losers.

檢視完整連鎖分析

行業概況 — 제약 / 바이오

行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

核心主題

  • •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
  • •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
  • •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성

近期催化劑

  • ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
  • ◆MRNA 암백신 FDA BLA 제출 예정